Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PETX

Aratana Therapeutics (PETX) Stock Price, News & Analysis

Aratana Therapeutics logo

About Aratana Therapeutics Stock (NASDAQ:PETX)

Advanced Chart

Key Stats

Today's Range
$4.92
$4.92
50-Day Range
$4.92
$4.92
52-Week Range
$3.30
$7.16
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$241.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aratana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PETX Stock News Headlines

PETX_old Historical Data
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
5 Stocks Under $10 to Trade for Big Breakouts
Aratana (PETX) Tops Q3 Earnings and Revenue Estimates
See More Headlines

PETX Stock Analysis - Frequently Asked Questions

Aratana Therapeutics Inc (NASDAQ:PETX) announced its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative trailing twelve-month return on equity of 12.99%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Corcept Therapeutics (CORT), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), ACADIA Pharmaceuticals (ACAD) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
11/01/2018
Today
7/11/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PETX
CIK
1509190
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.72 million
Net Margins
-33.47%
Pretax Margin
N/A
Return on Equity
-12.99%
Return on Assets
-10.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.66
Quick Ratio
5.32

Sales & Book Value

Annual Sales
$35.41 million
Price / Sales
6.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.07 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
49,000,000
Free Float
N/A
Market Cap
$241.08 million
Optionable
Optionable
Beta
1.40
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PETX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners